网站综合信息 afnm.com
    • 标题:
    • Affinium Pharmaceuticals 
    • 关键字:
    •  
    • 描述:
    •  
    • 域名信息
    • 域名年龄:22年6个月29天  注册日期:2001年10月25日  到期时间:2018年10月25日
      注册商:NETWORK SOLUTIONS, LLC. 
    • 备案信息
    • 备案号: 
    网站收录SEO数据
    • 搜索引擎
    • 收录量
    • 反向链接
    • 其他
    • 百度
    • 0  
    • 0  
    • 快照:2012-02-02  
    • Google
    • 61  
    • 8  
    • pr:4  
    • 雅虎
    • 0  
    •  
    •  
    • 搜搜
    • 0  
    •  
    •  
    • 搜狗
    • 1  
    •  
    • 评级:1/10  
    • 360搜索
    • 0  
    •  
    •  
    域名流量Alexa排名
    •  
    • 一周平均
    • 一个月平均
    • 三个月平均
    • Alexa全球排名
    • 6,258,537  
    • 平均日IP
    • 日总PV
    • 人均PV(PV/IP比例)
    • 反向链接
    • 27 
    • dmoz目录收录
    • Business/Biotechnology_and_Pharmaceuticals/Pharmaceuticals/Biopharmaceuticals/Manufacturing  

    • 流量走势图
    域名注册Whois信息

    afnm.com

    域名年龄: 22年6个月29天
    注册时间: 2001-10-25
    到期时间: 2018-10-25
    注 册 商: NETWORK SOLUTIONS, LLC.

    获取时间: 2013年10月10日 01:48:46
    Domain Name: AFNM.COM
    Registrar: NETWORK SOLUTIONS, LLC.
    Whois Server: whois.networksolutions.com
    Referral URL: http://www.networksolutions.com/en_US/
    Name Server: AUTH01.DNS.ACCELERATEDCONNECTIONS.COM
    Name Server: AUTH02.DNS.ACCELERATEDCONNECTIONS.COM
    Status: clientTransferProhibited
    Updated Date: 2013-07-31
    Creation Date: 2001-10-25
    Expiration Date: 2018-10-25

    >>> Last update of whois database: Wed, 2013-Oct-09 17:49:53 UTC <<<

    Welcome to the Network Solutions(R) Registrar WHOIS Server.

    The IP address from which you have visited the Network Solutions Registrar WHOIS
    database is contained within a list of IP addresses that may have failed
    to abide by Network Solutions' WHOIS policy. Failure to abide by this policy can
    adversely impact our systems and servers, preventing the processing of
    other WHOIS requests.

    To see the Network Solutions WHOIS Policy, click on or copy and paste the following
    URL into your browser:

    http://www.networksolutions.com/whois/index.jhtml

    If you feel that you have received this message in error, please email us using the online
    form at http://www.networksolutions.com/help/email.jsp with the following information:

    Whois Query: afnm.com
    YOUR IP address is 199.180.100.33
    Date and Time of Query: Wed Oct 09 13:03:2013-EDT-19
    Reason Code: IE
    其他后缀域名
    • 顶级域名
    • 相关信息
    网站首页快照(纯文字版)
    抓取时间:2019年09月20日 15:58:04
    网址:http://afnm.com/
    标题:Affinium Pharmaceuticals
    关键字:
    描述:
    主体:
    Skip to content
    Main Navigation:
    About Affinium 
    Corporate Information
    Management
    Board of Directors
    Scientific Advisors
    Programs 
    AFN–1252
    FabI Inhibitor Program
    Publications 
    News 
    News Archives
    Contact Us 
    TARGETED ANTIBIOTICS FOR SERIOUS INFECTIONS
    Affinium is a specialty pharmaceutical company developing a novel class of antibiotics that target the bacterial fatty acid synthesis pathway.  AFN-1252, our lead clinical compound, is a highly-potent, small molecule antibiotic for both oral and IV treatment of staphylococcal infections, including MRSA and all other drug-resistant strains.
    SEPTEMBER 5, 2013
    Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug, and the Closing of a Follow-on Financing Round 
    Click for PDF version (PDF 35KB)
    MARCH 20, 2013
    Affinium Pharmaceuticals Announces Positive Efficacy, Safety, and Tolerability Results from Phase 2a Clinical Trial of Oral AFN-1252 in Acute Bacterial Skin & Skin Structure Infections 
    Click for PDF version (PDF 245KB)
    MARCH 13, 2013
    Affinium Pharmaceuticals, Ltd., Announces the Appointments of Ed Mascioli, MD to the Position of Chief Executive Officer and Robert Radie to the Board of Directors 
    Click for PDF version (PDF 48KB)
    AUGUST 7, 2012
    Affinium Pharmaceuticals, Ltd., A nnounces Completion of Recruitment for Phase 2 Clinical Trial of AFN-1252 in Acute Bacterial Skin & Skin Structure Infections 
    Click for PDF version (PDF 28KB)
    Tab1
    Tab2
    Tab3
    Tab4
    More
    Kaplan, Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor
    Parsons, Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors
    More
    You can meet us at:
    ICAAC 2013, September 10-13, 2013. Denver, CO
    IDWeek 2013, October 2-6, 2013. San Francisco, CA
    Copyright © 2011 Affinium Pharmaceuticals
    Footer Navigation:
    Site Map
    Contact Us

    © 2010 - 2020 网站综合信息查询 同IP网站查询 相关类似网站查询 网站备案查询网站地图 最新查询 最近更新 优秀网站 热门网站 全部网站 同IP查询 备案查询

    2024-05-16 22:10, Process in 0.0112 second.